LBDA

December 2015 Newsletter

 

LBDU: Progress, Challenges and Opportunities in LBD Research

Watch Angela Taylor, the Director of Programs for the Lewy Body Dementia Association, talk about the moderated panel, LBDU: Progress, Challenges & Opportunities in LBD Research. This event was recorded and willl be posted on LBDA.org soon.

Support us with Amazon Smile

When you shop at AmazonSmile, Amazon donates 0.5% of the purchase price to Lewy Body Dementia Association Inc. Bookmark the link http://smile.amazon.com/ch/05-0577683 and support us every time you shop!

Axovant Sciences Plans Clinical Trials in LBD

Axovant Sciences Ltd., a clinical-stage biopharmaceutical company focused on the treatment of dementia, announced it is planning three clinical studies to address cognitive, behavioral and functional aspects of Lewy body dementia. Read Axovant’s full press release here.

New Federal Budget Dramatically Boosts Dementia Research Funding

An historic increase in dementia research funding was signed into law by a landmark federal spending deal last week. Thank you to all who responded to our Lobby for Change activity and contacted your members of Congress in October! Want to keep the momentum going? Click here to learn how!

International Conference a Huge Success

The International Dementia with Lewy Bodies (DLB) Conference took place in Ft. Lauderdale, FL on December 1-4, 2015, bringing together 400 LBD research stakeholders. Attendees included scientists from across the globe, clinicians, patients, caregivers plus representatives from the National Institutes of Health and for-profit corporations. Organized by Mayo Clinic and the Lewy Body Dementia Association, this is the first national or international conference on DLB ever held in the US.Learn more.

Does a Cancer Treatment offer Hope in LBD?

A small clinical study, intended to measure the safety of an FDA-approved treatment for leukemia, instead revealed symptom benefits in people with LBD. And in several cases, the improvement was rather remarkable, such as regaining the ability to talk, walk unaided or to feed oneself.

Since the study was not designed to measure effectiveness of the therapy, additional studies are needed before any recommendations can be made about the value of this treatment in LBD.

Learn more about this study from NPR.com.

 

Volunteer Corner

Lobby for Change: Speak Out at the Upcoming NIH Research Summit

LBD advocates are invited to attend and provide public comment on priorities for LBD research at the upcoming Alzheimer’s Disease-Related Dementias (ADRD) Summit, March 29-30, 2016 at the National Institutes of Health in Bethesda, MD.

The 2016 Summit will focus on LBD, frontotemporal dementias, mixed and vascular dementias, as well as health disparities. The goal is to review and assess the progress on the research recommendations developed by the 2013 workshop, refine and add new recommendations based on recent scientific discoveries, solicit public input, and update priorities and timelines for addressing

Registration for the summit is now open. Click here to learn more.